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Quality improvement has become a standard component of
clinical care over the past decadedand it has led to dramatic
improvements in care. Looking back, in 2001 Fonarow et al.
(1) reported that the use of statins following myocardial
infarction was a very disappointing 31.7%. This and other
observations of very low use of therapies well documented
to improve outcomesdsuch as aspirin, statins, and beta-
blockersdspurred the development of large-scale registries
and quality-improvement programs to increase the use of
these life-saving agents. Great successes have been seen
with these programs, which include CHAMP (Cardiac
Hospitalization Atherosclerosis Management Program) (2),
GAP (Guidelines Applied in Practice) (3), Get With
the Guidelines (4), CRUSADE (Can Rapid Risk Stratiﬁ-
cation of Unstable Angina Patients Suppress Adverse
Outcomes With Early Implementation of the ACC/AHA
Guidelines) (5), GRACE (Global Registry of Acute Coro-
nary Events) (6), ACTION (Acute Coronary Treatment
and Intervention Outcomes Network) Registry (7), and
REACH (Reduction of Atherothrombosis for Continued
Health) Registry (8). Over time, use of each of these agents
has improved to >90%.
See page 1791
Although such “report cards” have helped, they currently
monitor only the use of therapies proven effective >20 years
ago, and as such, they do not appear to keep pace with the
advances in medical therapeutics. This has prompted many
to ask: “How should we improve monitoring of quality?”
One approach is to add quality metrics to monitor the use of
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appropriateness of the new agents might not apply to all
patients in clinical practice, even within the approved indi-
cation, and that as such, some “clinical experience” should be
gained before new agents are added to our quality reports.
Others point out that while some new therapies are shown
to be more effective than standard therapies, they usually
cost more, and thus the lack of use may not be due to
a medical reason or to a lack of quality care, but to a simple
cost issue. One would not want a report of a lack of use of
a newer, expensive agent to be misconstrued as a failure of
the physician’s quality of care if it were due to cost
constraints of the patient or insurance company.
Another approach has been to look at composite measures
that include all of the initial quality metrics, whereby one
would monitor how many patients received all of the
guideline-recommended therapies. That is, what proportion
of patients (without contraindications to any one of the
agents) received all 4 classes of drugs (antiplatelet, beta-
blocker, statin, and angiotensin-converting enzyme inhib-
itor [ACEI] or angiotensin receptor blocker [ARB])? As one
might expect, the rates of compliance with the quality
metrics fall sharply from >90% for individual metrics to
40% to 60% for the combined metrics, (9) exposing in-
complete care, even at hospitals that seemed to provide very
high levels of quality. For example, in a patient with dia-
betes, glycemia may be well controlled with a hemoglobin
A1c <7%, but is the patient receiving aspirin, a statin, and
an ACEI/ARB? Similarly, in a patient with hypertension,
blood pressure (BP) may be controlled, but is the patient
receiving a statin (which has been shown to improve out-
comes) (10)? Thankfully, after these composite measures
are added to the reports generated for hospitals that par-
ticipate in registries and quality-improvement initiatives, the
rates of “defect-free care” improve (11).
In this issue of the Journal, Arnold et al. (12) have taken
things 1 step further, introducing the dose of these medica-
tions as a new quality measure. They note that, in the clinical
trials in which therapies have been shown to be beneﬁcial,
the doses of the therapies used are generally high (so as to
maximize their pharmacologic and then clinical effect), yet
in everyday clinical practice, the doses used are often lower.
Arnold et al. (12) analyzed data on 6,748 patients with
acute myocardial infarction discharged from 31 hospitals in
the United States between 2003 and 2008. The data were
collected at discharge and at 1-year follow-up in 2 registries:
PREMIER (Prospective Registry Evaluating Myocardial
Infarction: Events and Recovery) and TRIUMPH (Trans-
lational Research Investigating Underlying Disparities in
Acute Myocardial Infarction Patients’ Health Status). In
these populations, the use of beta-blockers, statins, and
ACEI/ARBs was >87% for each class of medications,
suggesting excellent quality of care.
But, as one might expect, the investigators found low
levels of use at “goal” doses: only one-third of patients
received doses of beta-blockers, statins, and ACEI/ARBs
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1803that were at least 75% of the target dose in the pivotal
trials. In addition, during follow-up, there was up-
titration of the dose in only about 25% of patients. As
a result, at 12 months after myocardial infarction, only
12%, 26%, and 32% of eligible patients were receiving the
target doses of beta-blockers, statins, and ACEI/ARBs,
respectively.
This low percentage seems as bad as the early registry data
on simple use of these agents (at any dose) from a decade
ago. In an effort to offer high-quality care, physicians typi-
cally check to ensure that all appropriate, guideline-
recommended medications are used, but they perhaps have
not paid as much attention to the doses of these medica-
tions, and thus this paper is a real eye-opener.
One strength of the analysis is that there is good rationale
for encouraging the use of higher doses. For statins (13) and
ACEIs (14), head-to-head, randomized trials have docu-
mented superior efﬁcacy with the higher versus lower doses.
A second strength is that the investigators excluded patients
whose systolic BP was <110 mm Hg, in whom it would
seemingly be difﬁcult to up-titrate the dose of an antihy-
pertensive medication.
A caution, though, is the “calibration” of the metric. They
have selected a seemingly generous cut point of “goal”
dosed75% of the planned target dose of the medication.
However, this level of compliance was not achieved even in
clinical trials. For example, in 1 recent ARB trial, the mean
achieved dose was 72% of the target dose (15). That is, only
50% of the patients reached 72% of the target dose. Thus, to
set a benchmark of wanting to see 100% patients reach this
“goal” dose is not really fair, considering that it was not
possible to achieve that level of compliance in the setting of a
carefully conducted clinical trial emphasizing up-titration
to the target dose. Thus, we have to be careful in setting
expectations and must do further work on the exact ben-
chmark of these quality measures. One could imagine, ﬁrst,
a careful survey of the actual trials (likely requiring asking the
primary investigators to query their trial database and to
report the proportion of patients in the actual trials who
achieved different percentage levels of the target dose).
Then, one would have a good benchmark to begin to
compare others in routine practice.
A second issue is that measuring this aspect of quality in
future registries will require more data from registriesdnot
just the simple presence of a medication on a medication list,
but also the dose, and then BP, heart rate, and lipid values.
These data should be available from electronic medical
records, but the validity of these measures as passively
collected in electronic medical records is not well deﬁned.
Thus, we have here an important new area of research in
quality measuresdwe now move beyond a “yes/no” metric to
look at the dose of each class of drugs to ensure full use of the
evidence-based therapy. More work is needed to establish
appropriate “goal” doses and benchmarks and to ensure that
data collected from electronic medical records are valid for
analysis. Nonetheless, this paper takes a major step forward andopens up a new way to try to maximize the beneﬁt of these life-
saving therapies for our patients.
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